

**APONTIS PHARMA AG Share buyback: Disclosure pursuant to Article 5 paragraph 1 lit. b) and paragraph 3 of the Regulation (EU) No. 596/2014 (MAR) in connection with Article 2 paragraph 2 and paragraph 3 of the Delegated Regulation (EU) No. 2016/1052**

**Purchase of own shares - 6<sup>th</sup> Interim notification**

**Monheim am Rhein, 1 August 2022.** In the period from 25 July 2022 up to and including 29 July 2022, a total of 3,500 shares were purchased under the Share Buyback Program 2022/II. The launch and the details of the Share Buyback Program 2022/II were published by way of an announcement dated 23 June 2022 pursuant to Article 5 paragraph 1 of Regulation (EU) No. 596/2014 and Article 2 paragraph 1 of the Delegated Regulation (EU) No. 2016/1052.

The total number of shares purchased in the period from 25 July 2022 up to and including 29 July 2022 per day, exchange, average price and volume in euros are as follows:

Date	Total number of shares purchased (number)	Average price (Euro)	Exchange	Volume (Euro) <sup>1</sup>
25/07/2022	227	11.2095	Xetra	2,544.55
26/07/2022	1.377	12.0196	Xetra	16,550.95
27/07/2022	918	12.0621	Xetra	11,073.00
28/07/2022	334	11.9939	Xetra	4,005.95
29/07/2022	644	11.7841	Xetra	7,588.95

1) Excluding acquisition costs

The total number of shares purchased to date as part of the Share Buyback Program 2022/II up to and including 29 July 2022 amounts to 38,347 shares.

The share buyback was carried out by Hauck Aufhäuser Lampe Privatbank AG.



Further details on the Share Buyback Program 2022 and the above transactions are published under the Corporate Governance section of the Company's Investor Relations website in accordance with Article 5 of Regulation (EU) No. 596/2014 and pursuant to Delegated Regulation (EU) No. 2016/1052 (<https://ir.apontis-pharma.de/websites/apontispharma/English/4000/corporate-governance.html>).

### **APONTIS PHARMA AG**

Investor Relations

[ir@apontis-pharma.de](mailto:ir@apontis-pharma.de)

T: +49 2173 89 55 4900

F: +49 2173 89 55 1521

Alfred-Nobel-Str. 10

40789 Monheim am Rhein

Germany

[apontis-pharma.de](http://apontis-pharma.de)

### **APONTIS PHARMA Presse Contact**

CROSS ALLIANCE communication GmbH

Sven Pauly

[ir@apontis-pharma.de](mailto:ir@apontis-pharma.de)

T: +49 89 125 09 0330